{"filings":[{"id":1570076,"accession_number":"0001493152-26-032802","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2026-07-10T15:43:15+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nomad Power increases Voyager fleet energy storage by up to 56% across all models","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Voyager Eagle and Falcon storage increased to 2.025 MWh each, up 56% from 1.3 MWh.","Voyager Hawk storage increased to 1.0 MWh, up 51% from 664 kWh.","Rated power output and footprint unchanged; deployment time remains under one hour.","Upgrade uses Octillion's prismatic LFP pack architecture with liquid cooling.","New capacity is standard on all new Voyager units going forward."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1414759,"accession_number":"0001493152-26-031870","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2026-07-02T20:00:46+00:00","items":["1.01","2.01","3.02","5.02","5.03","7.01","8.01","9.01"],"status":"ready","headline":"Lixte completes merger with NOMAD, changes name to Nomad Power Solutions, ticker to NMAD","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger closed July 1, 2026; NOMAD becomes wholly owned subsidiary of Lixte.","Consideration: 2,992,041 common shares and 50,366.07 Series D preferred shares (convertible into 50,366,070 common shares at $1.00/share).","Company name changes to Nomad Power Solutions effective July 3, 2026; ticker changes to NMAD on July 6, 2026.","John Travaglini appointed to board; continues as NOMAD CEO.","NOMAD has over 30 active projects across North America; addresses multi-billion-dollar market for mobile BESS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":"2026-07-02","daily_digest_url":"/daily/2026-07-02","daily_digest_rank":2},{"id":1138077,"accession_number":"0001493152-26-029308","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2026-06-18T20:00:23+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Lixte issues $6.5M secured note to NOMAD for pending merger","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Issued $6.5M secured promissory note to NOMAD in connection with pending merger.","Proceeds to repay NOMAD's existing debt and for working capital.","Note matures 30 days, extends automatically while merger agreement in effect; upon merger close, note offset against merger consideration.","If merger terminated due to Company breach, note repayable in 6 months; if NOMAD breach, due in 3 days.","Press release provides update on NOMAD acquisition; transaction expected to close shortly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1083518,"accession_number":"0001493152-26-028878","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2026-06-16T20:00:25+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Lixte Biotechnology to acquire NOMAD Transportable Power Systems, pivoting to energy storage","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Consideration: up to 50,500 Series D Convertible Preferred shares ($1,000/sh, convertible at $1.00) plus up to 3M common shares.","Closing condition: Lixte must hold at least $16.5M unrestricted cash; proxies for 33% of common stock to approve conversion.","NOMAD revenue grew ~175% YoY in 2025, projected ~135% YoY growth in 2026; ~75% of sales inbound and >30 active opportunities.","Company to be renamed NOMAD Power Solutions; John Travaglini named CEO of merger sub and board member.","NOMAD first-to-market with mobile, utility-grade 1 MW BESS; UL 9540 validated, bypassing permanent BESS permitting delays."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":863076,"accession_number":"0001493152-26-027307","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2026-06-04T21:01:23+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Lixte Biotechnology closes ~$16.6M registered direct offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$16.6 million from sale of 2,625,362 shares and pre-funded warrants.","Offering priced at $6.31 per common share and $6.3099 per pre-funded warrant.","Pre-funded warrants exercisable immediately at $0.0001 per share.","Net proceeds to be used for general corporate purposes and working capital.","Offering closed on June 4, 2026 under existing shelf registration statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":760158,"accession_number":"0001493152-26-026544","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2026-06-01T12:55:34+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Lixte Biotechnology pivots to AI energy infrastructure; appoints Denham Capital founder to board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company will seek strategic acquisition partner for clinical-stage pharma/med-tech operations.","Stuart D. Porter, founder of Denham Capital (over $12B committed), joins board effective May 29, 2026.","Strategy targets power equipment/services for hyperscale AI data centers; NERC projects 224 GW demand increase.","LIXT expects to maintain Nasdaq listing under ticker LIXT during transformation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92297,"accession_number":"0001493152-26-017833","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2026-04-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Lixte Biotechnology cancels 500,000 options, awards equal RSUs vesting immediately to CEO, CFO, and directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Geordan Pursglove: 350,000 options cancelled, 350,000 RSUs awarded; CFO Peter Stazzone: 50,000 each.","Directors Holloway, Primus, Felix, Sawyer: each 25,000 options cancelled and RSUs awarded.","RSUs granted under 2020 Stock Incentive Plan and vested immediately on April 15, 2026.","Committee states swap provides better retention/incentive for officers and directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103051,"accession_number":"0001493152-26-011829","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Lixte Biotechnology raises CEO base salary to $360,000 effective Jan 1, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Geordan Pursglove's annual base salary increased from $240,000 to $360,000.","Increase effective retroactively to January 1, 2026; initial payment includes catch-up amount.","Amendment approved by Compensation Committee and Board of Directors on March 18, 2026.","Employee may elect to receive salary in cash or restricted shares based on closing price.","Amendment filed as Exhibit 10.1 to Form 8-K dated March 18, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103050,"accession_number":"0001493152-26-009526","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Lixte restructures Liora acquisition; issues 700k shares, $440k cash, Bitcoin/Ethereum for 80% stake","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Amended Share Exchange consolidates prior transactions; Lixte acquires 800 of 1,000 Liora shares (80%).","Consideration includes 700,000 common shares, $440,000 cash, 10.56 Bitcoin and 300 Ethereum to Orbit Capital.","Liora holds assets for LIGHT proton-based radiotherapy system acquired from Advanced Oncotherapy PLC.","Orbit retains 20% of Liora after terminating original royalty agreement and Series C Preferred exchange.","Agreement effective November 21, 2025, executed March 6, 2026 to unify multiple transaction documents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103049,"accession_number":"0001493152-26-007268","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"LIXTE appoints Sidney Braun CEO of Liora; GBP 50K signing bonus, GBP 25K monthly retainer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Braun becomes CEO of Liora Technologies Europe Ltd., effective Feb 13, 2026.","Signing bonus of GBP 50,000 plus monthly retainer of GBP 25,000 (both excl. VAT).","If Liora is sold, Braun gets 20% of net purchase price via Allocation Deed.","Braun helped create Liora and facilitated LIXTE's acquisition of Liora's assets in Nov 2025.","He brings 20+ years healthcare experience; previously built Remicade infusion network."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119281,"accession_number":"0001493152-25-029778","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2025-12-31T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Lixte exchanges 2,700 Series C preferred for 700K common shares and 20% of Liora subsidiary","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Orbit Capital Inc. exchanged 2,700 Series C Preferred shares for 700,000 Lixte common shares and 200 ordinary shares of Liora (20% of Liora).","Upon closing, all Series C Preferred shares were cancelled and no longer outstanding.","Lixte retained 800 ordinary shares of Liora after the exchange.","Transaction was exempt from registration under Section 4(a)(2) and Regulation D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119280,"accession_number":"0001493152-25-028999","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Lixte expands ovarian cancer trial to 42 patients; expects initial data in H1 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment No.2 to collaborative study doubles enrollment from 21 to 42 patients for LB-100 + dostarlimab trial in ovarian clear cell carcinoma.","Lixte enters new Collaborative Research Agreement with MD Anderson; pays milestone payments up to $1.5M ($500k per event) plus 3.75% royalty on net profit.","GSK and Lixte provide drugs at no cost to institution for expanded 42-patient study; no additional GSK payments beyond original 21 subjects.","Initial data from first 21 patients expected in first half of 2026; trial led by MD Anderson includes Northwestern as second site."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119279,"accession_number":"0001493152-25-028850","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2025-12-22T23:59:59+00:00","items":["1.01","1.02","8.01","9.01"],"status":"ready","headline":"Lixte Biotechnology raises $4.3M in registered direct offering; terminates royalty agreement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$4.3M from 1,051,342 Common Units at $4.09/unit; each unit includes one share (or Pre-Funded Warrant) and one Common Warrant (exercise $3.96, 60-month term).","Offering priced at market under Nasdaq rules; expected close Dec 19, 2025.","Terminated Royalty Agreement with Orbit Capital Inc. (dated Nov 24, 2025); both parties released from claims.","Net proceeds to be used for general corporate purposes and working capital.","Spartan Capital Securities acted as sole placement agent with 6% fee and $85K legal expense reimbursement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119278,"accession_number":"0001493152-25-027219","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Lixte shareholders elect all five directors, ratify auditor, approve stock plan increase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All five director nominees elected: Geordan Pursglove, Jason Sawyer, Dr. Michael Holloway, Lourdes Felix, Guy Primus.","Ratification of Weinberg & Company as auditor approved with 3,080,890 for, 36,370 against, 79 abstain.","Stock plan amendment to increase shares from 2.75M to 3.5M approved with 1,984,980 for, 74,134 against, 1,500 abstain.","Broker non-votes of ~1.06M on director elections and plan amendment.","Meeting had 3,117,339 shares present out of 5,635,467 shares entitled to vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.15,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119277,"accession_number":"0001493152-25-024996","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2025-11-25T23:59:59+00:00","items":["1.01","2.01","3.02","5.03","7.01","9.01"],"status":"ready","headline":"LIXTE acquires Liora Technologies' proton therapy platform; consideration includes stock, crypto, cash, royalty","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Consideration: 2,700 Series C Preferred shares (convertible to 2.7M common), 10.56 BTC + 300 ETH, $440K cash, and 10% royalty on net revenue up to $45M.","Liora's LiGHT proton therapy system installed at Daresbury Laboratory in UK; $300M+ invested to date.","Acquisition closed Nov 24, 2025; Liora becomes wholly owned subsidiary of LIXTE.","Series C Preferred is non-voting, convertible subject to 19.99% limit until shareholder approval at 2026 annual meeting.","CEO says LiGHT platform complements LB-100 pipeline and enables potential recurring revenue model."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135861,"accession_number":"0001641172-25-027109","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"LIXTE makes $2.6M initial cryptocurrency purchase to diversify treasury","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Purchased 10.5 Bitcoin and 300 Ethereum for total of $2.6 million.","Board approved increased allocation of up to 50% of treasury to cryptocurrencies.","Cryptocurrency now represents approximately 43.6% of LIXTE's treasury holdings.","Strategy aims to strengthen treasury position and enable transactions across digital mediums."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135860,"accession_number":"0001641172-25-026448","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Lixte appoints new CFO, two board members; relocates HQ to Boca Raton","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rene Bernards, Regina Brown, Bas van der Baan resigned from Board; CFO Robert Weingarten resigned; all departures amicable.","Peter Stazzone named CFO ($150k annual salary + options for 50k shares); Geordan Pursglove named President (already CEO/Chairman).","Lourdes Felix and Guy Primus join Board; Felix chairs Audit Committee; Primus on Audit and Compensation.","Corporate headquarters moved to Boca Raton, Florida to reduce costs and improve efficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135859,"accession_number":"0001641172-25-024680","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2025-08-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"LIXTE raises $6.5M, adds new CEO/board members, regains Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed two financings raising $6.5M gross ($5M private placement + $1.5M registered direct); proceeds for working capital.","Regained compliance for continued listing on Nasdaq Capital Market.","Geordan Pursglove appointed Chairman and CEO in June 2025; Bas van der Baan becomes President and CSO.","Nature published findings validating LB-100 mechanism; new pre-clinical study with Netherlands Cancer Institute.","Jason Sawyer and Michael Holloway joined Board as independent directors; Forman and Yen moved to Scientific Advisory Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135858,"accession_number":"0001641172-25-023628","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lixte Biotechnology updates treasury policy to allocate up to 25% to Bitcoin and other digital assets","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved allocating up to 25% of corporate treasury to cryptocurrencies including Bitcoin.","Company will hold crypto assets with a fully regulated and compliant custodian.","CEO Geordan Pursglove cites long-term potential to hedge treasury and deliver shareholder returns.","Timing and size of purchases will depend on market conditions; policy retains flexibility.","Lixte is a clinical-stage biotech; treasury policy shift is a strategic capital allocation initiative."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135857,"accession_number":"0001641172-25-020408","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2025-07-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lixte appoints two new independent directors; CMO resigns effective July 31","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board adds Jason Sawyer and Dr. Michael Holloway as independent directors, designated by Series B Preferred Stock holders.","Dr. Stephen Forman and Dr. Yun Yen resign from Board, will serve on Scientific Advisory Committee.","Mr. Sawyer named Chairman of Compensation Committee and member of Audit Committee.","Chief Medical Officer Dr. Jan Schellens resigns effective July 31, 2025; consulting agreement terminated.","Resignations not due to any disagreement with company operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135856,"accession_number":"0001641172-25-019900","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2025-07-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"LIXTE Biotechnology regains Nasdaq equity compliance after $6.5M capital raise","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq hearings panel notice of compliance with Listing Rule 5550(b)(1) requiring min $2.5M equity.","Compliance achieved after closing $5.0M placement (July 2) and $1.5M direct offering (July 8).","Subject to Panel Monitor through July 15, 2026; further deficiency triggers immediate hearing requirement.","CEO states regaining compliance underscores financial health as clinical trials progress in ovarian, colon, sarcoma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135855,"accession_number":"0001641172-25-018684","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2025-07-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nature publication validates LIXTE's PP2A approach in ovarian and colorectal cancers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nature study: OCCC patients with PPP2R1A mutations had significantly better overall survival on immunotherapy.","PPP2R1A inactivates PP2A, the target of LB100, providing scientific validation for LIXTE's ongoing clinical trials.","LIXTE is evaluating LB100 + checkpoint inhibitors in two trials: with GSK (dostarlimab) for OCCC and with Roche (atezolizumab) for colon cancer.","First clinical results from these trials expected in the second half of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135854,"accession_number":"0001641172-25-018256","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2025-07-08T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Lixte Biotechnology closes $1.5M registered direct offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed registered direct offering of 974,026 shares (or pre-funded warrants) at $1.54 per share for gross proceeds of ~$1.5M.","Offering comprised 210,675 common shares and pre-funded warrants for 763,351 shares; closed July 8, 2025.","Net proceeds to be used for general corporate purposes and working capital.","Spartan Capital Securities acted as exclusive placement agent; TroyGould PC provided legal counsel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135853,"accession_number":"0001641172-25-017653","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Lixte closes $5.0M private placement of common stock, preferred and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $5.0M; $4.0M received at closing July 2, 2025; $1.0M due upon SEC registration effectiveness.","Offering includes 2,382,084 common shares (or pre-funded warrants), 3,573,130 Series B convertible preferred shares, and 6,355,214 common warrants exercisable at $1.00/share.","Series B preferred shares bear 8% cumulative non-compounding dividend, convertible 1:1, and grant holders two board seats.","Net proceeds to be used for general corporate purposes and working capital; Spartan Capital served as placement agent.","Post-offering, company believes stockholders' equity exceeds $2.5M and awaits Nasdaq compliance determination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152838,"accession_number":"0001641172-25-015346","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Lixte appoints Geordan Pursglove as CEO, contingent on Nasdaq financing by July 3","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Geordan Pursglove appointed CEO and Chairman; Bastiaan van der Baan resigns as CEO, remains President and CSO.","Employment agreement with Pursglove has $240K annual salary, plus potential bonus and stock option grant for 350K shares.","Van der Baan's existing stock option for 250K shares fully vested; exercise period extended to one year after service ends.","Pursglove's appointment automatically terminates if Lixte fails to complete a financing enabling Nasdaq listing by July 3, 2025.","If financing condition not met, van der Baan to be reinstated as CEO and Chairman, and Pursglove's option grant cancelled."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152837,"accession_number":"0001641172-25-011701","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Lixte receives conversion notice for 350,000 Series A Preferred shares into 72,917 common shares","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Notice received May 16, 2025 for 350,000 Series A Convertible Preferred shares.","Issued to an investor in 2015 and 2016; converts into 72,917 shares of common stock.","Conversion dilutes existing common equity by approximately 72,917 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152836,"accession_number":"0001641172-25-005466","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2025-04-18T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nasdaq Panel grants Lixte extension to July 3, 2025 for equity compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Lixte received extension from Nasdaq Hearings Panel after April 3 hearing on equity deficiency.","Must demonstrate minimum $2.5M stockholders' equity by July 3, 2025 to remain listed.","Common stock (LIXT) and warrants (LIXTW) continue trading on Nasdaq during extension.","Company pursuing measures but warns no assurance of regaining compliance; delisting risk persists."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171653,"accession_number":"0001641172-25-001763","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lixte launches pre-clinical study of LB-100 to target pre-cancerous cells with NKI","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New pre-clinical study tests if initiated cells with mutant RAS oncogene can be eliminated by LB-100.","Collaboration with Netherlands Cancer Institute; led by Dr. René Bernards, NKI senior scientist and LIXTE board member.","Study in animal models expands on LIXTE’s ongoing clinical trials for ovarian and colorectal cancers.","LB-100 has shown patient tolerance with little toxicity in Phase 1 clinical trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171652,"accession_number":"0001641172-25-000971","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"LIXTE updates LB-100 clinical progress; two new trials started, $1.05M offering completed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in Phase 1b/2 trial combining LB-100 with GSK's dostarlimab for ovarian clear cell carcinoma.","First patient dosed in colorectal trial at Netherlands Cancer Institute supported by Roche for MSI Low metastatic CRC.","Received Notice of Allowance from USPTO for patent combining LB-100 with immunotherapies; also exclusive license agreement with NIH.","Completed registered direct offering raising $1.05M for working capital and general corporate purposes.","Two publications in Cancer Discovery and EMBO support LB-100's mechanism to force cancer cells to become vulnerable to immunotherapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171651,"accession_number":"0001493152-25-010282","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2025-03-14T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Lixte Biotechnology relieved of $3.1M funding obligation for Phase 2 sarcoma study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment No. 1 to clinical trial agreement with GEIS relieves Lixte of approx $3,095,000 obligation for randomized Phase 2 portion.","Phase 1b recruitment completed in Q3 2024; initial toxicity and preliminary efficacy data expected Q4 2025.","Study overall expected to be completed and report prepared by Dec 31, 2026.","Lixte's lead compound LB-100 studied with doxorubicin for advanced soft tissue sarcomas."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171650,"accession_number":"0001493152-25-009786","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Lixte terminates at-the-market equity facility with WallachBeth Capital; effective March 18, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Notice of termination of Sales Agreement with WallachBeth Capital LLC given on March 7, 2025.","Termination becomes effective ten days after notice, i.e., March 18, 2025.","Company plans to explore alternatives to raise additional equity capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171649,"accession_number":"0001493152-25-009782","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lixte reports new pre-clinical data on LB-100 activation and potential biomarker for patient response","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enzyme discovered that converts LB-100 to active metabolite endothall, published in BioXriv and Int'l J. Pharmaceutics.","Findings open potential biomarker strategy to identify patients most likely to respond to LB-100.","LB-100 also spontaneously converts via slow hydrolysis; enzymatic conversion inside cell expedites activation.","Clinical trials for LB-100 in ovarian and colorectal cancer continue; CEO says data will help optimize patient selection."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171648,"accession_number":"0001493152-25-008203","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lixte adds Northwestern's Lurie Cancer Center as second site for LB-100 + Dostarlimab trial in ovarian clear cell cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lurie Cancer Center (Northwestern University) opened as second clinical site for LB-100 plus GSK's Dostarlimab.","First patient dosed at Lurie; patient recruitment is underway. Lead investigator: Dr. Emily M. Hinchcliff.","Trial originally began in January 2024 at MD Anderson Cancer Center; lead investigator Dr. Amir Jazaeri.","Trial targets ovarian clear cell carcinoma, a disease with high unmet medical need.","LIXTE's proprietary compound LB-100 is combined with immunotherapy to enhance effectiveness."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171647,"accession_number":"0001493152-25-007865","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2025-02-21T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Lixte Biotechnology fails Nasdaq equity minimum; plans appeal to avoid delisting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Failed to meet Nasdaq's $2.5M stockholders' equity requirement by Feb 18, 2025 extension deadline.","Received Staff determination letter on Feb 19, 2025; intends to appeal and request a hearing.","Appeal will automatically stay delisting of common stock (LIXT) and warrants (LIXTW) pending Panel decision.","Nasdaq Hearings Panel may grant additional extension until Aug 18, 2025 to regain compliance.","Company had previously submitted a compliance plan in Oct 2024 after initial Aug 2024 deficiency notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171646,"accession_number":"0001493152-25-006285","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Lixte Biotechnology raises $1.05M in registered direct offering and private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 434,784 shares at $2.415/share and warrants for 434,784 shares at $2.29/share.","Warrants are immediately exercisable for a five-year term; gross proceeds ~$1.05M.","Offering closed on Feb 13, 2025; net proceeds for working capital and general corporate purposes.","H.C. Wainwright acted as exclusive placement agent with 7.5% cash fee and warrants.","Private placement warrants and underlying shares unregistered, resale registration to be filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171645,"accession_number":"0001493152-25-001069","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Lixte Biotechnology enters $1.7M at-the-market sales agreement with WallachBeth Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered ATM sales agreement to sell up to $1.7M of common stock.","Agent commission 3.5% of gross sales; up to $50K expense reimbursement.","Net proceeds for working capital and development of lead compound LB-100.","Sales at market prices on Nasdaq or other methods per Rule 415.","Company not obligated to sell any shares under the agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188648,"accession_number":"0001493152-24-052249","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2024-12-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lixte Biotechnology VP and COO Eric Forman resigns effective Dec 31, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eric Forman resigned as VP and COO of Lixte Biotechnology Holdings, effective December 31, 2024.","Resignation is for personal reasons; no disagreement with company operations, policies, or practices.","Employment agreement dated July 15, 2020 (amended Aug 12, 2020 and Nov 6, 2022) terminates on Dec 31, 2024.","No replacement or interim appointment has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188647,"accession_number":"0001493152-24-051050","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Lixte Biotechnology announces annual meeting results; all director nominees elected","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All five director nominees (Forman, Yen, Brown, Bernards, van der Baan) elected with >653K votes for each.","Ratification of Weinberg & Company as auditor passed with 1.33M votes for, 56K against.","Advisory approval of executive compensation passed with 672K for, 40K against.","Broker non-votes totaled ~670K on director and compensation proposals; none on auditor ratification.","Annual meeting held December 19, 2024; no other business items reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188646,"accession_number":"0001493152-24-048292","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2024-12-02T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Lixte pauses NKI/Oncode collaboration until Phase 1b trial starts; budget cut to €100K","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment 3 pauses research activities under the development collaboration with NKI and Oncode Institute.","Collaboration resumes upon first patient dosing in Phase 1b trial combining LB-100 with a WEE1 inhibitor in metastatic colorectal cancer.","Termination date revised to one year from first patient dosing; annual budget reduced from €250,000 to €100,000.","Parties will study translational data from patient samples in NKI clinical trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188645,"accession_number":"0001493152-24-042172","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2024-10-23T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Lixte Biotechnology gets Nasdaq extension to Feb 18, 2025 to meet equity requirement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified non-compliance with $2.5M minimum stockholders' equity requirement.","Company submitted compliance plan; Nasdaq granted extension until February 18, 2025.","Filed S-1 registration statement to raise up to $4.0M in equity capital.","Failure to evidence compliance by March 31, 2025 may lead to delisting.","Common stock and warrants continue trading on Nasdaq under LIXT and LIXTW."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205107,"accession_number":"0001493152-24-035144","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2024-09-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"LIXTE receives USPTO Notice of Allowance for patent covering LB-100 with cancer immunotherapies","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["U.S. Patent application 16/467,721 titled 'Oxabicycloheptanes for Modulation of Immune Response' allowed.","Patent covers combining LIXTE's LB-100 PP2A inhibitor with various innovative cancer immunotherapies.","CEO Bastiaan van der Baan says patent bolsters IP portfolio and commitment to cancer innovation.","LB-100 is being tested in clinical trials with Roche's atezolizumab (colon cancer) and GSK's dostarlimab (ovarian cancer).","Follows exclusive patent license agreement earlier this year with NINDS and NCI of the NIH."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205106,"accession_number":"0001493152-24-033870","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2024-08-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lixte dosed first patient with LB-100 in new colorectal cancer trial with NKI and Roche support","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dosed first patient in clinical trial NCT06012734 for MSI Low metastatic colorectal cancer.","Trial collaboration with Netherlands Cancer Institute (NKI); Roche supplies atezolizumab (Tecentriq).","Second pharma-funded LB-100 immunotherapy trial; earlier GSK trial for clear cell ovarian cancer started 2024.","Aims to bring immunotherapy to ~85% of colorectal cancer patients currently unresponsive."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205105,"accession_number":"0001493152-24-033705","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2024-08-23T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Lixte Biotechnology receives Nasdaq deficiency notice for stockholders' equity requirement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Notice from Nasdaq on August 19, 2024 for non-compliance with Listing Rule 5550(b)(1) requiring minimum $2,500,000 stockholders' equity.","Company has 45 days to submit a plan to regain compliance; Nasdaq may grant up to 180-day extension.","If plan not accepted or compliance not regained, Company can request hearing which stays suspension or delisting.","Trading on Nasdaq continues under symbols LIXT and LIXTW with no immediate effect.","Company intends to take reasonable measures but no assurance of regaining compliance with continued listing standards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205104,"accession_number":"0001493152-24-033144","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2024-08-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"LIXTE reports Roche-backed trial, new CMO, and SCLC trial termination","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New clinical trial with Netherlands Cancer Institute, supported by Roche, testing LB-100 + atezolizumab in metastatic colorectal cancer.","Dr. Jan Schellens appointed Chief Medical Officer effective Aug 1, 2024; 25+ years oncology drug development experience.","Preclinical data in EMBO Reports shows LB-100 can turn immunologically 'cold' tumors 'hot', enhancing immunotherapy benefit.","Small cell lung cancer trial at City of Hope terminated due to limited patient accrual; exploring alternative sites."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205103,"accession_number":"0001493152-24-027085","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2024-07-12T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Lixte terminates City of Hope trial agreement for LB-100 Phase 1b; seeks new sites","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Terminated Clinical Research Support Agreement with City of Hope effective July 8, 2024.","Agreement covered Phase 1b trial of LB-100 combined with Carboplatin/Etoposide/Atezolizumab for extensive-stage small cell lung cancer.","Company plans to explore alternative clinical trial sites to continue the study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205102,"accession_number":"0001493152-24-026924","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2024-07-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lixte Biotechnology switches director compensation from cash to stock options for Q2-Q4 2024 to preserve cash","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Director Rene Bernards agrees to receive equity compensation instead of cash starting Q2 2024, aligning with other non-officer directors.","Board Compensation Plan amended: non-officer directors will receive stock options for Q2, Q3, Q4 2024 in lieu of cash.","Options vest immediately, expire in 5 years; exercise price based on quarter-end closing market price.","Change intended to preserve cash; Board and Compensation Committee may extend beyond Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221991,"accession_number":"0001493152-24-023834","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"LIXTE collaborates with Roche and NKI on trial combining LB-100 with atezolizumab in MSI Low colon cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Trial (NCT06012734) will test LB-100 plus Roche's PD-L1 inhibitor atezolizumab in immunotherapy-unresponsive MSI Low metastatic colon cancer.","LIXTE provides LB-100; Roche provides atezolizumab via imCORE Network; NKI is principal investigator.","About 85% of colon cancers are MSI Low; LB-100 may sensitize these tumors to immunotherapy, expanding treatment options.","This is second recent pharma-backed trial combining LB-100 with immunotherapy; GSK is funding a separate trial in clear cell ovarian cancer.","New pre-clinical data in EMBO Reports showed LB-100 can turn immunologically 'cold' tumors 'hot'."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221990,"accession_number":"0001493152-24-023798","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Lixte enters Phase 1b/2 trial of LB-100 + atezolizumab for metastatic colorectal cancer with NKI","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Trial combines Lixte's PP2A inhibitor LB-100 with Roche's atezolizumab; company provides LB-100 only.","Roche provides atezolizumab and financial support; Lixte has no obligation to reimburse trial costs.","Phase 1b/2 study led by Dr. Neeltje Steeghs at NKI in Amsterdam; opens by June 30, 2024.","Patient accrual up to 24 months; maximum 37 metastatic microsatellite stable colorectal cancer patients.","Dose escalation to determine RP2D; expansion phase evaluates safety, tolerability, and pharmacokinetics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221989,"accession_number":"0001493152-24-022709","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["1.01","5.02","8.01","9.01"],"status":"ready","headline":"Lixte Biotechnology appoints Jan Schellens as Chief Medical Officer, effective August 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Jan Schellens named CMO effective Aug 1, 2024, succeeding James Miser who departs on July 31, 2024.","Consulting agreement: €104,000 annual compensation, plus options for 15,000 shares at Nasdaq closing price on July 1, 2024, vesting quarterly over 3 years.","Schellens brings 25+ years oncology experience, former CMO at Byondis B.V., board member of Dutch Medicines Evaluation Board.","He will lead clinical trial oversight, regulatory strategy, and serve as primary medical monitor.","Agreement provides for services 2 days per week, based in Netherlands; term until terminated by either party with 60 days' notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221988,"accession_number":"0001493152-24-021837","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2024-05-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lixte Biotechnology notifies CMO James Miser of non-renewal; employment ends July 31, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. James Miser's employment agreement not renewed; CMO role ends July 31, 2024.","Lixte intends to appoint a new Chief Medical Officer effective August 1, 2024.","Notice of non-renewal provided to Dr. Miser on May 24, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":76217021.77725857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-05-29T23:59:59+00:00|221988"}